HIV shots tested in pregnancy: a step toward easier treatment for moms

NCT ID NCT07637942

Not yet recruiting Disease control Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how long-acting injectable HIV drugs (cabotegravir and rilpivirine) work in the body during pregnancy and after childbirth. About 40 pregnant women with HIV will receive the shots every 4 weeks. The goal is to measure drug levels and see if they stay effective, helping to keep the mother healthy and reduce the risk of passing HIV to the baby.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Long-acting injectable cabotegravir and rilpivirine
What this could lead to: If successful, this could show that long-acting HIV shots work well during pregnancy, offering a convenient option for pregnant women with HIV.
What could go wrong: This is a small, early-phase study (40 participants) focused on drug levels, not on proving the drugs prevent HIV transmission. Results may not apply to all women, and there are unknown risks during pregnancy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Site 4001, Lurie Children's Hospital of Chicago CRS

Chicago, Illinois, 60614, United States
Site 4601, University of California, UC San Diego CRS

La Jolla, California, 92093, United States
Site 5013, Jacobi Medical Center Bronx

The Bronx, New York, 10461, United States
Site 5030, Emory University School of Medicine

Atlanta, Georgia, 30322, United States
Site 5048, University of Southern California

Los Angeles, California, 90033, United States
Site 5052, University of Colorado

Aurora, Colorado, 80045, United States
Site 5092, Johns Hopkins University

Baltimore, Maryland, 21287, United States
Site 5128, Baylor College of Medicine/Texas Children's Hospital

Houston, Texas, 77030, United States
Site 6201, University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Site 6501, St Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.